- Home
- LENZ vs IMNM Comparison
LENZ vs IMNM Comparison
Compare LENZ & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LENZ
- IMNM
- Stock Information
- Founded
- LENZ 2019
- IMNM 2006
- Country
- LENZ United States
- IMNM United States
- Employees
- LENZ N/A
- IMNM N/A
- Industry
- LENZ Medicinal Chemicals and Botanical Products
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- LENZ Health Care
- IMNM Health Care
- Exchange
- LENZ Nasdaq
- IMNM Nasdaq
- Market Cap
- LENZ 664.5M
- IMNM 747.7M
- IPO Year
- LENZ 2021
- IMNM 2020
- Fundamental
- Price
- LENZ $24.67
- IMNM $11.71
- Analyst Decision
- LENZ Strong Buy
- IMNM Strong Buy
- Analyst Count
- LENZ 6
- IMNM 4
- Target Price
- LENZ $35.40
- IMNM $28.75
- AVG Volume (30 Days)
- LENZ 168.0K
- IMNM 706.7K
- Earning Date
- LENZ 08-14-2024
- IMNM 11-07-2024
- Dividend Yield
- LENZ N/A
- IMNM N/A
- EPS Growth
- LENZ N/A
- IMNM N/A
- EPS
- LENZ N/A
- IMNM N/A
- Revenue
- LENZ N/A
- IMNM $10,784,000.00
- Revenue This Year
- LENZ N/A
- IMNM N/A
- Revenue Next Year
- LENZ N/A
- IMNM N/A
- P/E Ratio
- LENZ N/A
- IMNM N/A
- Revenue Growth
- LENZ N/A
- IMNM 62.73
- 52 Week Low
- LENZ $2.01
- IMNM $6.93
- 52 Week High
- LENZ $31.00
- IMNM $30.96
- Technical
- Relative Strength Index (RSI)
- LENZ 50.64
- IMNM 34.65
- Support Level
- LENZ $25.13
- IMNM $11.81
- Resistance Level
- LENZ $31.00
- IMNM $12.46
- Average True Range (ATR)
- LENZ 2.09
- IMNM 0.62
- MACD
- LENZ 0.15
- IMNM -0.06
- Stochastic Oscillator
- LENZ 26.31
- IMNM 13.89
About LENZ LENZ Therapeutics Inc. Common Stock
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.